User login
Key clinical point: Autonomic symptoms were prevalent in patients with episodic or chronic migraine but demonstrated no significant correlation with headache frequency, treatment response, or reversion from chronic to episodic migraine.
Major finding: Overall, 60.5% of patients reported a Composite Autonomic Symptom Scale (COMPASS-31) score of ≥30. The median monthly headache days (P = .002) and Migraine Disability Assessment Score (P = .01) reduced significantly during the study period but change in the mean weighted COMPASS-31 score was not significant (P = .885), with no correlation observed between the COMPASS-31 score and monthly headache frequency or reversion from chronic to episodic migraine.
Study details: This was a prospective longitudinal cohort study including 43 patients with episodic or chronic migraine who completed 12 months of treatment and follow-up surveys.
Disclosures: This study did not report the source of funding. Four authors declared receiving funding, grants, or payment for developing educational presentations, serving on advisory boards, or being involved in clinical trials sponsored by various sources.
Source: Ray JC et al. Autonomic symptoms in migraine: Results of a prospective longitudinal study. Front Neurol. 2022;13:1036798 (Nov 3). Doi: 10.3389/fneur.2022.1036798
Key clinical point: Autonomic symptoms were prevalent in patients with episodic or chronic migraine but demonstrated no significant correlation with headache frequency, treatment response, or reversion from chronic to episodic migraine.
Major finding: Overall, 60.5% of patients reported a Composite Autonomic Symptom Scale (COMPASS-31) score of ≥30. The median monthly headache days (P = .002) and Migraine Disability Assessment Score (P = .01) reduced significantly during the study period but change in the mean weighted COMPASS-31 score was not significant (P = .885), with no correlation observed between the COMPASS-31 score and monthly headache frequency or reversion from chronic to episodic migraine.
Study details: This was a prospective longitudinal cohort study including 43 patients with episodic or chronic migraine who completed 12 months of treatment and follow-up surveys.
Disclosures: This study did not report the source of funding. Four authors declared receiving funding, grants, or payment for developing educational presentations, serving on advisory boards, or being involved in clinical trials sponsored by various sources.
Source: Ray JC et al. Autonomic symptoms in migraine: Results of a prospective longitudinal study. Front Neurol. 2022;13:1036798 (Nov 3). Doi: 10.3389/fneur.2022.1036798
Key clinical point: Autonomic symptoms were prevalent in patients with episodic or chronic migraine but demonstrated no significant correlation with headache frequency, treatment response, or reversion from chronic to episodic migraine.
Major finding: Overall, 60.5% of patients reported a Composite Autonomic Symptom Scale (COMPASS-31) score of ≥30. The median monthly headache days (P = .002) and Migraine Disability Assessment Score (P = .01) reduced significantly during the study period but change in the mean weighted COMPASS-31 score was not significant (P = .885), with no correlation observed between the COMPASS-31 score and monthly headache frequency or reversion from chronic to episodic migraine.
Study details: This was a prospective longitudinal cohort study including 43 patients with episodic or chronic migraine who completed 12 months of treatment and follow-up surveys.
Disclosures: This study did not report the source of funding. Four authors declared receiving funding, grants, or payment for developing educational presentations, serving on advisory boards, or being involved in clinical trials sponsored by various sources.
Source: Ray JC et al. Autonomic symptoms in migraine: Results of a prospective longitudinal study. Front Neurol. 2022;13:1036798 (Nov 3). Doi: 10.3389/fneur.2022.1036798